12 completed, 3 active not recruiting, 2 recruiting, 2 unknown. 10 Phase 2, 6 Phase 3, 3 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Sexual Infantilism: new trials by email Literature Review of Sexual Infantilism trials Research Report on Sexual Infantilism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child | Phase 3 | Not yet recruiting | University Hospital, Angers | 50 | 2026-11-01 | 2026-09-29 |
| A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) Bivamelagon - Hypothalamic Obesity | Phase 2 | Enrolling by invitation | Rhythm Pharmaceuticals, Inc. | 25 | 2025-11-10 | 2026-02-10 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | 39 | 2025-09-23 | 2026-02-12 |
| Tirzepatide in PWS, HO and GNSO Tirzepatide - Prader-Willi Syndrome, Hypothalamic Obesity | Phase 4 | Recruiting | Grace Kim | 36 | 2025-05-01 | 2025-09-16 |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| Open-Label Extension Study of Setmelanotide Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-10-21 | 2026-07-15 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Bivamelagon, Placebo - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-07-11 | 2026-10-30 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome | Phase 1 / Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 111 | 2024-03-05 | 2026-10-09 |
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity Setmelanotide, Placebo - Hypothalamic Obesity | Phase 3 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 143 | 2023-04-26 | 2026-08-10 |
| The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Saxenda - Panhypopituitarism, Craniopharyngioma | Early Phase 1 | Unknown | Seoul National University Hospital | 50 | 2022-11-28 | 2024-01-23 |
| Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) Melatonin - Oxytocin Deficiency, Hypopituitarism | Not applicable | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 40 | 2022-04-01 | 2024-04-09 |
| Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Placebo, Tesomet - Hypothalamic Obesity | Phase 2 | Withdrawn | Saniona | 2021-11-11 | 2022-12-13 | |
| Open-Label Study of Setmelanotide in Hypothalamic Obesity Setmelanotide - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 18 | 2021-06-07 | 2025-02-07 |
| Neuromodulation for Hypothalamic Obesity Hypothalamic Deep Brain Stimulation - Craniopharyngioma, Hypothalamic Obesity | Not applicable | Withdrawn | University of British Columbia | 2019-06-01 | 2020-11-02 | |
| Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Exenatide, Placebo - Craniopharyngiomas, Hypothalamic Obesity | Phase 3 | Completed | University Hospital, Bordeaux | 42 | 2017-01-11 | 2026-05-22 |
| Intranasal Oxytocin in Hypothalamic Obesity Syntocinon, Placebo (for Syntocinon) - Craniopharyngioma, Hypothalamic Obesity | Phase 2 | Completed | Shana McCormack, MD | 18 | 2016-10-01 | 2022-10-05 |
| A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity Hypothalamic Obesity | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2016-06-29 | 2018-09-17 | |
| Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Exenatide, placebo - Hypothalamic Obesity | Phase 3 | Completed | Seattle Children's Hospital | 42 | 2016-03-01 | 2022-05-05 |
| Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage Exenatide - Hypothalamic Obesity, Diabetes Mellitus | Not applicable | Unknown | Huashan Hospital | 10 | 2012-12-01 | 2013-10-22 |
| Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Exenatide - Obesity, Overweight | Phase 2 | Completed | Vanderbilt University Medical Center | 10 | 2012-06-01 | 2017-03-03 |
Showing 20 of 23. Sign in to see all of them.
Craniopharyngioma (8) · Obesity (6) · Prader-Willi Syndrome (3) · Combined Pituitary Hormone Deficiency (1) · Diabetes Insipidus, Neurogenic (1) · Diabetes Mellitus (1) · Hypopituitarism (1) · Hypothalamic Neoplasms (1) · Metabolic Syndrome (1) · Motor Activity (1) · Optic Nerve Hypoplasia (1) · Overweight (1) · Septo-Optic Dysplasia (1) · Social Isolation (1)
Congenital Abnormalities (23) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Disorders of Sex Development (23) · Endocrine System Diseases (23) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Gonadal Disorders (23) · Gonadal Dysgenesis (23) · Hypogonadism (23) · Male Urogenital Diseases (23) · Urogenital Abnormalities (23) · Urogenital Diseases (23) · Nutritional and Metabolic Diseases (9) · Neoplasms (8) · Neoplasms by Histologic Type (8)
Exenatide (5) · setmelanotide (4) · Diazoxide (1) · Liraglutide (1) · Melatonin (1) · Metformin (1) · Metoprolol (1) · Octreotide (1) · Oxytocin (1) · Phentermine (1) · Qsymia (1) · Tesofensine (1) · Tirzepatide (1) · semaglutide (1)
Rhythm Pharmaceuticals, Inc. (7) · Seattle Children's Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Children's Hospitals and Clinics of Minnesota (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Grace Kim (1) · Huashan Hospital (1) · Novartis (1) · Saniona (1) · Seoul National University Hospital (1) · Shana McCormack, MD (1) · The Hospital for Sick Children (1) · University Hospital, Angers (1) · University Hospital, Bordeaux (1) · University of British Columbia (1)
United States (14) · United Kingdom (4) · Canada (3) · France (2) · China (1) · Germany (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1)
David Meeker, MD (6) · Shana E McCormack, MD (2) · Ashley Shoemaker, M.D. (1) · Blandine Gatta-Cherifi, Pr (1) · Christian L Roth, MD (1) · Christian Roth, MD (1) · David Meeker (1) · Jill Hamilton, MD (1) · M. Jennifer Abuzzahab, MD (1) · Paul Perez, Dr (1) · Sophie Guillaume, MS (1)
PMID 27133664, PMID 38450721, PMID 42418774, PMID 42528856, PMID 42821228